Acute effects of blood pressure elevation on insulin clearance in normotensive healthy subjects

被引:10
作者
O'Callaghan, CJ [1 ]
Komersova, K [1 ]
Louis, WJ [1 ]
机构
[1] Univ Melbourne, Dept Med, Austin & Repatriat Med Ctr, Clin Pharmacol & Therapeut Unit, Heidelberg, Vic, Australia
关键词
insulin; hypertension; essential; sympathetic nervous system; renin-angiotensin system; metabolism;
D O I
10.1161/01.HYP.31.1.104
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Reduced clearance of insulin from plasma contributes to the hyperinsulinemia associated with essential hypertension (EH); however, the association between impaired insulin clearance and EH remains unexplained. Whether elevated blood pressure (BP) affects insulin clearance is unknown; therefore, we used the hyperinsulinemic euglycemic clamp to determine the effects of BP elevation on insulin clearance and sensitivity in eight healthy volunteers. Placebo infusion increased mean BP by 2.6+/-1.6 mm Hg, which was significantly less than rises produced by phenylephrine, an alpha(1)-adrenoceptor agonist (+11+/-1.8 mm Hg, P<.05), or by angiotensin II (+13+/-1.3 mmHg, P<.01). Although beta-adrenoceptor stimulation with isoproterenol did not change mean BP (+3.6 mm Hg, P=NS), it significantly increased systolic pressure (+23+/-2.8 mm Hg versus +2.3+/-4.6 mm Hg with placebo P<.01). Insulin secretion (ie, C-peptide concentrations) was not affected by any of the treatments; however, phenylephrine significantly reduced the metabolic clearance rate of insulin (MCEinsulin) (16.6+/-1.0 mL/kg per minute with placebo versus 13.6+/-0.7 mL/kg per minute with phenylephrine, P<.01) and thereby increased plasma insulin concentrations (66+/-5.1 mu U/mL with placebo versus 79+/-4.1 mu U/mL with phenylephrine, P<.05). Phenylephrine also increased glucose utilization (42+/-5.8 mu mol/kg per minute during placebo versus 58+/-4.8 mu mol/kg per minute during phenylephrine, P<.05); however, this was proportional to the increased insulin concentrations; therefore, insulin sensitivity was unchanged. MCRinsulin and plasma insulin concentrations were not affected by angiotensin II; however, glucose utilization increased to 51+/-2.7 mu mol/kg per minute (P<.01 versus placebo), indicating insulin sensitivity was increased. MCRinsulin was unaffected by isoproterenol. Thus, alpha-adrenergic stimulation but not increased BP per se is a potent regulator of insulin clearance and plasma insulin concentrations.
引用
收藏
页码:104 / 109
页数:6
相关论文
共 42 条
[11]   INSULIN-RESISTANCE SYNDROME - POSSIBLE KEY ROLE OF BLOOD-FLOW IN RESTING MUSCLE [J].
GANROT, PO .
DIABETOLOGIA, 1993, 36 (09) :876-879
[12]   IMPAIRED GLUCOSE-METABOLISM AND REDUCED INSULIN-CLEARANCE IN ELDERLY HYPERTENSIVES [J].
GIUGLIANO, D ;
SALVATORE, T ;
PAOLISSO, G ;
BUONINCONTI, R ;
TORELLA, R ;
VARRICCHIO, M ;
DONOFRIO, F .
AMERICAN JOURNAL OF HYPERTENSION, 1992, 5 (06) :345-353
[13]  
GOLDSTEIN BJ, 1992, INT TXB DIABETES MEL, P357
[14]  
GRAHAMESMITH DG, 1992, OXFORD TXB CLIN PHAR, P44
[15]   SIMILAR REDUCTION OF 1ST-PHASE AND 2ND-PHASE B-CELL RESPONSES AT 3 DIFFERENT GLUCOSE-LEVELS IN TYPE-II DIABETES AND THE EFFECT OF GLICLAZIDE THERAPY [J].
HOSKER, JP ;
RUDENSKI, AS ;
BURNETT, MA ;
MATTHEWS, DR ;
TURNER, RC .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1989, 38 (08) :767-772
[16]   ADRENERGIC-RECEPTORS IN HUMAN-LIVER PLASMA-MEMBRANES - PREDOMINANCE OF BETA-2-RECEPTOR AND ALPHA-1-RECEPTOR SUBTYPES [J].
KAWAI, Y ;
POWELL, A ;
ARINZE, IJ .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1986, 62 (05) :827-832
[17]   STUDIES ON THE INSULIN-ANTAGONISTIC EFFECT OF CATECHOLAMINES IN NORMAL MAN - EVIDENCE FOR THE IMPORTANCE OF BETA-2-RECEPTORS [J].
LAGER, I ;
ATTVALL, S ;
ERIKSSON, BM ;
VONSCHENK, H ;
SMITH, U .
DIABETOLOGIA, 1986, 29 (07) :409-416
[18]   MODE OF ACTION OF CLONIDINE UPON ISLET FUNCTION - DISSOCIATED EFFECTS UPON THE TIME COURSE AND MAGNITUDE OF INSULIN RELEASE [J].
LECLERCQMEYER, V ;
HERCHUELZ, A ;
VALVERDE, I ;
COUTURIER, E ;
MARCHAND, J ;
MALAISSE, WJ .
DIABETES, 1980, 29 (03) :193-200
[19]   Essential hypertension is associated with decreased insulin clearance and insulin resistance [J].
Lender, D ;
ArauzPacheco, C ;
AdamsHuet, B ;
Raskin, P .
HYPERTENSION, 1997, 29 (01) :111-114
[20]  
Mark AL, 1996, J HYPERTENS, V14, pS159